ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2016-5-134-146ssmu-742Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSСвязана ли микрофлора кишечника с болезнью Паркинсона?Is gut microbiota associated with Parkinson’s disease?ТяхтА. В.TyakhtA. V.

канд. биол. наук, ст. науч. сотрудник лаборатории биоинформатики,

119435, г. Москва, ул. Малая Пироговская, 1а

PhD, Senior Researcher, Laboratory of Bioinformation,

1a, Malaya Pirogovskaya Str., Mosсow, 119992

АлифироваВ. М.AlifirovaV. M.

д-р мед. наук, профессор, зав. кафедрой неврологии и нейрохирургии,

634050, г. Томск, Московский тракт, 2

MD, Professor, Head of the Neurology and Neurosurgery Department,

2, Moscow Trakt, Tomsk, 634050

ЖуковаН. Г.ZhukovaN. G.

д-р мед. наук, профессор кафедры неврологии и нейрохирургии,

634050, г. Томск, Московский тракт, 2

MD, Professor, Neurology and Neurosurgery Department,

2, Moscow Trakt, Tomsk, 634050

ЖуковаИ. А.ZhukovaI. A.

канд. мед. наук, доцент кафедры неврологии и нейрохирургии,

634050, г. Томск, Московский тракт, 2

PhD, Associate Professor, Neurology and Neurosurgery Department,

2, Moscow Trakt, Tomsk, 634050

irzhukova@inbox.ruЛатыповаА. В.LatypovaA. V.

ординатор кафедры неврологии и нейрохирургии,

634050, г. Томск, Московский тракт, 2

Neurology Resident,

2, Moscow Trakt, Tomsk, 634050

МироноваЮ. С.IzhboldinaO. P.

аспирант кафедры неврологии и нейрохирургии,

634050, г. Томск, Московский тракт, 2

Post-graduate Student,

2, Moscow Trakt, Tomsk, 634050

ПетровВ. А.PetrovV. A.

мл. науч. сотрудник ЦНИЛ,

634050, г. Томск, Московский тракт, 2

Junior Researcher, Central Research Laboratory,

2, Moscow Trakt, Tomsk, 634050

ИжболдинаО. П.MironovaYu. S.

аспирант кафедры неврологии и нейрохирургии,

634050, г. Томск, Московский тракт, 2

Post-graduate Student, Neurology and Neurosurgery Department,

2, Moscow Trakt, Tomsk, 634050

ТитоваМ. А.TitovaM. A.

канд. мед. наук, доцент кафедры неврологии и нейрохирургии,

634050, г. Томск, Московский тракт, 2

PhD, Associate Professor, Neurology and Neurosurgery Department,

2, Moscow Trakt, Tomsk, 634050

НикитинаМ. А.NikitinaM. A.

аспирант кафедры неврологии и нейрохирургии,

634050, г. Томск, Московский тракт, 2

Post-graduate Student, Neurology and Neurosurgery Department,

2, Moscow Trakt, Tomsk, 634050

КострюковаЕ. С.KostryukovaE. S.

канд. биол. наук, зав. лабораторией постгеномных исследований в биологии,

119435, г. Москва, ул. Малая Пироговская, 1а

PhD, Head of Laboratory Postgenomics Research in Biology,

1a, Malaya Pirogovskaya Str., Mosсow, 119992

ДорофееваЮ. Б.DorofeevaYu. B.

мл. науч. сотрудник ЦНИЛ,

634050, г. Томск, Московский тракт, 2

Junior Researcher, Central Research Laboratory,

2, Moscow Trakt, Tomsk, 634050

СалтыковаИ. В.SaltykovaI. V.

канд. мед. наук, науч. сотрудник ЦНИЛ,

634050, г. Томск, Московский тракт, 2

PhD, Researcher, Central Research Laboratory,

2, Moscow Trakt, Tomsk, 634050

СазоновА. Э.SazonovA. E.

д-р мед наук, зам. проректора Управления научной политики и организации научных исследований,

119991, г. Москва, Ленинские Горы, 1

MD, Deputy Vice-rector,

1, Leninskiye Gory, Moscow, 119991

Федеральный научно-клинический центр физико-химической медицины Федерального медико-биологического агентстваРоссияResearch Institute of Physico-Chemical Medicine of Russian Federal Medico-Biological Agency (RIPCM)Russian FederationСибирский государственный медицинский университетРоссияSiberian State Medical UniversityRussian FederationМосковский государственный университет имени М.В. ЛомоносоваРоссияLomonosov Moscow State UniversityRussian Federation201631012017155134146Copyright © Тяхт А.В., Алифирова В.М., Жукова Н.Г., Жукова И.А., Латыпова А.В., Миронова Ю.С., Петров В.А., Ижболдина О.П., Титова М.А., Никитина М.А., Кострюкова Е.С., Дорофеева Ю.Б., Салтыкова И.В., Сазонов А.Э., 20172017Тяхт А.В., Алифирова В.М., Жукова Н.Г., Жукова И.А., Латыпова А.В., Миронова Ю.С., Петров В.А., Ижболдина О.П., Титова М.А., Никитина М.А., Кострюкова Е.С., Дорофеева Ю.Б., Салтыкова И.В., Сазонов А.Э.Tyakht A.V., Alifirova V.M., Zhukova N.G., Zhukova I.A., Latypova A.V., Izhboldina O.P., Petrov V.A., Mironova Y.S., Titova M.A., Nikitina M.A., Kostryukova E.S., Dorofeeva Y.B., Saltykova I.V., Sazonov A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/742

Болезнь Паркинсона (БП) – это нейродегенеративное заболевание со сложным патогенезом. В поисках причин развития нейродегенеративного и нейровоспалительного процесса все большую роль отводят оси «микробиота – кишечник – мозг».

Цель исследования – выявление связи между составом микробиоты кишечника и клиническими проявлениями БП.

Материал и методы

Материал и методы. Было обследовано 89 пациентов с диагнозом БП. Был учтен анамнез, тяжесть болезни по шкале Хен и Яра, произведена оценка степени проявлений БП с помощью Унифицированной шкалы оценки проявлений БП. Дополнительно пациентами были заполнены карты оценки самочувствия пациента с болезнью Паркинсона (Parkinson’s Well-Being Map). Для оценки консистенции каловых масс использовалась Бристольская шкала. Выделение ДНК проводилось в соответствии с ранее описанной методикой. Подготовка библиотек и ампликонное секвенирование маркерного вариабельного участка V3–V4 бактериальных генов 16S рРНК проводились на приборе MiSeq (Illumina, США) согласно стандартному протоколу производителя. Фильтрация прочтений по баллам качества и их таксономическая классификация проведены с помощью программного обеспечения QIIME версии 1.9.0. Осуществлена оценка α- и β-разнообразия, проанализированы различия в представленности отдельных таксономических единиц между группами пациентов при использовании программного обеспечения IBM SPSS Statistics 23.1.

Результаты

Результаты. Выявлены значимые различия в представленности семи родов между группами пациентов с разными формами заболевания. Всего было идентифицировано около 40 родов, относительная представленность которых в сумме составила 54,8% от общего микробиотического состава кишечника, причем часть родов имели корреляции с клиническими проявлениями заболевания.

Заключение

Заключение. Вероятно, эти микроорганизмы могут являться непосредственными участниками патогенеза БП и требуют более пристального внимания в свете новых тенденций воздействия на организм путем коррекции микробиотического состава кишечника.

Parkinson’s disease (PD) is a neurodegenerative disorder with a complex pathogenesis. Today more and more studies are focusing on microbiota-gut-brain axis searching the causes of neurodegenerative and neuroinflammatory processes.

The aim of our study is to determine the relationship between the composition of gut microbiota and clinical manifestations of PD.

Materials and methods. We examined 89 patients with a PD diagnosis. Clinical assessment was performed including medical history collection, rating disease stage using Hoehn and Yahr scale. Motor and nonmotor symptoms as well as possible complication were examined using the Unified Parkinson’s Disease Rating Scale. In addition, patients were asked to fill in Parkinson’s Well-Being Map and defecation diary that included Bristol scale. DNA isolation was performed in accordance with the method described. Preparation of libraries and amplicon sequencing of marker variable region V3–V4 of bacterial 16S rRNA genes was performed with MiSeq device (Illumina, USA) according to manufacturer’s standard protocol. Filtering readings by quality and their taxonomic classification were carried out using QIIME version 1.9.0 software. The assessment of statistical differences in abundance of taxonomic units among the groups of patients was performed using IBM SPSS Statistics 23.1 software.

As a result, we have identified significant differences in the abundance of seven genera among the groups of patients with different forms of the disease. We identified about 40 genera constituting 54.8% of the intestinal microbiota, that had a correlation with the clinical manifestations of the disease. These microorganisms might be involved in the pathogenesis of PD and, thus, require more clinical research in the light of emerging new methods of altering microbiotic composition by correcting dysbiosis to improve disease management and outcome. 

болезнь Паркинсонамикробиомнемоторные проявлениянейродегенерацияParkinson’s diseasemicrobiomenonmotor symptomsneurodegenerationгрант ФЦП №14.604.21.0150 «Выявление биомаркеров микробиотического сообщества кишечника для ранней, доклинической диагностики БП»ReferencesLema Tomé C.M. et al. Inflammation and α-synuclein’s prion-like behavior in Parkinson’s disease—is there a link? // Molecular Neurobiology. 2012; 47 (2): 561–574.Lema Tomé C.M. et al. Inflammation and α-synuclein’s prion-like behavior in parkinson’s disease—is there a link? // Molecular Neurobiology. 2012; 47 (2): 561–574.Visanji N.P. et al. The prion hypothesis in Parkinson’s disease: braak to the future // Acta Neuropathologica Communications. 2013; 1: 2–2.Visanji N.P. et al. The prion hypothesis in Parkinson’s disease: Braak to the future // Acta Neuropathologica Communications. 2013; 1: 2–2.Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinson’s disease // J. Neuroimmune Pharmacol. 2013; 8 (1): 189–201.Blandini F. Neural and Immune Mechanisms in the Pathogenesis of Parkinson’s Disease // J. Neuroimmune Pharmacol. 2013; 8 (1): 189–201.Иллариошкин С.Н. Конформационные болезни мозга. Москва: Янус-К, 2002: 248.Illarioshkin S.N. Konformacionniye bolezni mozga [Conformational disoreders of the brain]. Moscow: Yanus-K, 2002: 248 (in Russian).Barnum C.J., Tansey M.G. Modeling neuroinflammatory pathogenesis of Parkinson’s disease // Progress in Brain Research. 2010; 184: 113–132.Barnum C.J., Tansey M.G. Modeling neuroinflammatory pathogenesis of Parkinson’s disease // Progress in Brain Research. 2010; 184: 113–132.Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes // Mol. Neurobiol. 2014; 49 (1): 28–38.Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes // Mol. Neurobiol. 2014; 49 (1): 28–38.Klingelhoefer L., Reichmann H. Pathogenesis of Parkinson disease [mdash] the gut-brain axis and environmental factors // Nat. Rev. Neurol. 2015; 11 (11): 625–636.Klingelhoefer L., Reichmann H. Pathogenesis of Parkinson disease [mdash] the gut-brain axis and environmental factors // Nat. Rev. Neurol. 2015; 11 (11): 625–636.Svensson E. et al. Vagotomy and subsequent risk of Parkinson’s disease // Annals of Neurology. 2015; 78 (4): 522–529.Svensson E. et al. Vagotomy and subsequent risk of Parkinson’s disease // Annals of Neurology. 2015; 78 (4): 522–529.Del Tredici K., Braak H. Lewy pathology and neurodegeneration in premotor Parkinson’s disease // Mov. Disord. 2012; 27 (5); 597–607.Del Tredici K., Braak H. Lewy pathology and neurodegeneration in premotor Parkinson’s disease // Mov. Disord. 2012; 27 (5); 597–607.Cersosimo M. et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms // J. Neurol. 2013; 260 (5): 1332–1338.Cersosimo M. et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms // J. Neurol. 2013; 260 (5): 1332–1338.Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson’s disease // Parkinsonism & Related Disorders. 17 (1): 10–15.Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson’s disease // Parkinsonism & Related Disorders. 17 (1): 10–15.Tillisch K. The effects of gut microbiota on CNS function in humans // Gut Microbes. 2014; 5 (3): 404–410.Tillisch K. The effects of gut microbiota on CNS function in humans // Gut Microbes. 2014; 5 (3): 404–410.Mao Y.-K. et al. Bacteroides fragilis polysaccharide A is necessary and sufficient for acute activation of intestinal sensory neurons // Nat. Commun. 2013; 4: 1465.Mao Y.-K. et al. Bacteroides fragilis polysaccharide A is necessary and sufficient for acute activation of intestinal sensory neurons // Nat. Commun. 2013; 4: 1465.Barrett E. et al. γ-Aminobutyric acid production by culturable bacteria from the human intestine // Journal of Applied Microbiology. 2012; 113 (2): 411–417.Barrett E. et al. γ-Aminobutyric acid production by culturable bacteria from the human intestine // Journal of Applied Microbiology. 2012; 113 (2): 411–417.Bhargava P., Mowry E. Gut microbiome and multiple sclerosis // Curr. Neurol. Neurosci Rep. 2014; 14 (10): 1–8.Bhargava P., Mowry E. Gut Microbiome and Multiple Sclerosis // Curr. Neurol. Neurosci Rep. 2014; 14 (10): 1–8.Ochoa-Repáraz J. et al. Induction of a regulatory B. cell population in experimental allergic encephalomyelitis by alteration of the gut commensal microflora // Gut Microbes. 2010; 1 (2): 103–108.Ochoa-Repáraz J. et al. Induction of a regulatory B. cell population in experimental allergic encephalomyelitis by alteration of the gut commensal microflora // Gut Microbes. 2010; 1 (2): 103–108.Scheperjans F. et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype // Mov. Disord. 2015; 30 (3): 350–358.Scheperjans F. et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype // Mov. Disord. 2015; 30 (3): 350–358.Goetz C.G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr Staging Scale: status and recommendations. The Movement Disorder Society Task Force on rating scales for Parkinson’s disease // Movement Disorders. 2004; 19 (9): 1020–1028.Goetz C.G. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. The Movement Disorder Society Task Force on rating scales for Parkinson’s disease // Movement Disorders. 2004; 19 (9): 1020–1028.World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects // Bulletin of the World Health Organization. 2001; 79 (4): 373–374.World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects // Bulletin of the World Health Organization. 2001; 79 (4): 373–374.Goetz C.G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results // Movement Disorders. 2008; 23 (15): 2129–2170.Goetz C.G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results // Movement Disorders. 2008; 23 (15): 2129–2170.Egshatyan L. et al. Gut microbiota and diet in patients with different glucose tolerance // Endocrine Connections. 2016; 5 (1): 1–9.Egshatyan L. et al. Gut microbiota and diet in patients with different glucose tolerance // Endocrine Connections. 2016; 5 (1): 1–9.Caporaso J.G. et al. QIIME allows analysis of high-throughput community sequencing data // Nature Methods. 2010; 7 (5): 335–336.Caporaso J.G. et al. QIIME allows analysis of high-throughput community sequencing data // Nature Methods. 2010; 7 (5): 335–336.DeSantis T.Z. et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB // Applied and Environmental Microbiology. 2006; 72 (7): 5069–5072.DeSantis T.Z. et al. Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB // Applied and Environmental Microbiology. 2006; 72 (7): 5069–5072.Ritari J. et al. Improved taxonomic assignment of human intestinal 16S rRNA sequences by a dedicated reference database // BMC Genomics. 2015; 16 (1): 1–10.Ritari J. et al. Improved taxonomic assignment of human intestinal 16S rRNA sequences by a dedicated reference database // BMC Genomics. 2015; 16 (1): 1–10.Paulson J.N. et al. Differential abundance analysis for microbial marker-gene surveys // Nat. Meth. 2013; 10 (12): 1200–1202.Paulson J.N. et al. Differential abundance analysis for microbial marker-gene surveys // Nat. Meth. 2013; 10 (12): 1200–1202.Jiang H. et al. Altered fecal microbiota composition in patients with major depressive disorder // Brain, Behavior and Immunity. 2015; 48: 186–194.Jiang H. et al. Altered fecal microbiota composition in patients with major depressive disorder // Brain, Behavior and Immunity. 2015; 48: 186–194.Stasi C. et al. Altered neuro-endocrine–immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model // J. Gastroenterol. 2012; 47 (11): 1177–1185.Stasi C. et al. Altered neuro-endocrine–immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model // J. Gastroenterol. 2012; 47 (11): 1177–1185.Finegold S. et al. Clinical importance of Bilophila wadsworthia // European Journal of Clinical Microbiology and Infectious Diseases. 1992; 11 (11): 1058–1063.Finegold S. et al. Clinical importance of Bilophila wadsworthia // European Journal of Clinical Microbiology and Infectious Diseases. 1992; 11 (11): 1058–1063.Summanen P.H. et al. Bilophila wadsworthia isolates from clinical specimens // Clinical Infectious Diseases. 1995; 20 (Supplement 2): 210–211.Summanen P.H. et al. Bilophila wadsworthia Isolates from Clinical Specimens // Clinical Infectious Diseases. 1995; 20 (Supplement 2): 210–211.Joyce S.A., Gahan C.G.M. The gut microbiota and the metabolic health of the host // Current Opinion in Gastroenterology. 2014; 30 (2).Joyce S.A., Gahan C.G.M. The gut microbiota and the metabolic health of the host // Current Opinion in Gastroenterology. 2014; 30 (2).Del Chierico F. et al. Mediterranean diet and health: food effects on gut microbiota and disease control // International Journal of Molecular Sciences. 2014; 15 (7).Del Chierico F. et al. Mediterranean diet and health: food effects on gut microbiota and disease control // International Journal of Molecular Sciences. 2014; 15 (7).Erickson A.R. Characterization of the human host gut microbiome with an integrated genomics / Proteomics Approach. 2011.Erickson A.R. Characterization of the human host gut microbiome with an integrated genomics / Proteomics Approach. 2011.Mondot S. et al. Structural robustness of the gut mucosal microbiota is associated with Crohn’s disease remission after surgery // Gut. 2016; 65 (6): 954–962.Mondot S. et al. Structural robustness of the gut mucosal microbiota is associated with Crohn’s disease remission after surgery // Gut. 2016; 65 (6): 954–962.Ino K. et al. Bacteremia due to Leuconostoc pseudomesenteroides in a patient with acute lymphoblastic leukemia: case report and review of the literature // Case Reports in Hematology. 2016; 2016: 7648628.Ino K. et al. Bacteremia due to Leuconostoc pseudomesenteroides in a patient with acute lymphoblastic leukemia: case report and review of the literature // Case Reports in Hematology. 2016; 2016: 7648628.Davin-Regli A., Pagès J.-M. Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment // Frontiers in Microbiology. 2015; 6: 392.Davin-Regli A., Pagès J.-M. Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment // Frontiers in Microbiology.Konikoff T., Gophna U. Oscillospira: а central, enigmatic component of the human gut microbiota // Trends in Microbiology. 24 (7): 523–524.; 6: 392.Duncan S.H. et al. Oxalobacter formigenes and its potential role in human health // Applied and Environmental Microbiology. 2002; 68 (8): 3841–3847.Konikoff T., Gophna U. Oscillospira: А central, enigmatic component of the human gut microbiota // Trends in Microbiology. 24 (7): 523–524.Duncan S.H. et al. Oxalobacter formigenes and its potential role in human health // Applied and Environmental Microbiology. 2002; 68 (8): 3841–3847.Duncan S.H. et al. Oxalobacter formigenes and its potential role in human health // Applied and Environmental Microbiology. 2002; 68 (8): 3841–3847.

The authors declare that there are no conflicts of interest present.